OUR TEAM
Meet Our Team
OUR TEAM
Dr. Hasib Salah-Uddin – Chief Executive Officer
Dr. Hasib Salah-Uddin is an accomplished drug discovery scientist and biotechnology leader with deep expertise in assay development, molecular screening, and translational pharmacology. His work spans oncology as well as psychiatric, neurological, and metabolic disorders, with a career at the intersection of academic innovation and pharmaceutical development.
Dr. Salah-Uddin previously served as Director of Assay Development and Molecular Screening at the Drug Discovery Institute within the Mount Sinai Health System in New York, where he led high-throughput discovery platforms for novel therapeutic targets. His industry and academic appointments include research roles at The Scripps Research Institute, University of Miami, GlaxoSmithKline, and Eli Lilly, where he contributed to multiple early-stage drug programs across diverse therapeutic areas.
He brings a strategic vision to oncology R&D rooted in both scientific rigor and cross-sector collaboration, driving innovation from bench to clinic.
Education
Ph.D., Medicine & Therapeutics – University of Aberdeen
B.Sc. (Hons), Biochemistry – University College London
Dr. Brown – Chairman of the Board
Dr. Brown is a distinguished cancer biologist and serial biotech entrepreneur with over 30 years of experience in oncology drug discovery and development. He played a pivotal role in the advancement and FDA approval of Synribo®(omacetaxine mepesuccinate), a plant-derived therapy for chronic myeloid leukemia.
He was the founder and President of ChemGenex Therapeutics, which merged to form ChemGenex Pharmaceuticals (ASX:CXS / NASDAQ:CXSP), and previously served as Chief Scientific Officer and Director at DelMar Pharmaceuticals (now Kintara Therapeutics, NASDAQ:KTRA). He has also chaired the Board of Mountain View Pharmaceuticals. Earlier in his career, Dr. Brown co-founded Matrix Pharmaceutical, Inc., where he held executive roles in scientific affairs and discovery research.
In academia, Dr. Brown held faculty positions at Harvard Medical School and conducted research at Stanford University School of Medicine, contributing to advances in radiology and cancer imaging.
Education
Ph.D., Radiation and Cancer Biology – New York University
M.S., Cell Biology – New York University
B.A., Biology and Chemistry – New York University
Daniel Larsen, CFA - Vice President of Business Development
Daniel Larsen is a seasoned investment professional with over 25 years of experience managing capital for high-net-worth individuals and institutional clients. He has held leadership roles at premier financial institutions including JP Morgan, Morgan Stanley, and UBS, where he specialized in portfolio construction, risk management, and strategic advisory.
Dan began his career at Boston Research and Management through a referral from his graduate school mentor. Over six years, he advanced from investment analyst to Chief Investment Officer, where he oversaw $500 million in equity and fixed income assets. His disciplined, research-driven approach and fiduciary mindset have made him a trusted advisor across market cycles.
In parallel to his financial career, Dan later founded and scaled a successful restoration company, bringing operational rigor and entrepreneurial insight to business building. He continues to advise on strategic financial matters while remaining active in his local community, teaching breathwork and meditation as part of his passion for wellness.